Maximec 10 mg/ml solution for injection for pigs

País: Irlanda

Idioma: inglés

Fuente: HPRA (Health Products Regulatory Authority)

Cómpralo ahora

Descargar Ficha técnica (SPC)
26-06-2023
Descargar DSU (DSU)
26-06-2023

Ingredientes activos:

Ivermectin

Disponible desde:

Bimeda Animal Health Limited

Código ATC:

QP54AA01

Designación común internacional (DCI):

Ivermectin

Dosis:

1 percent weight/volume

formulario farmacéutico:

Solution for injection

tipo de receta:

POM: Prescription Only Medicine as defined in relevant national legislation

Área terapéutica:

ivermectin

Estado de Autorización:

Authorised

Fecha de autorización:

2004-10-19

Ficha técnica

                                1
_[Version 9,03/2022] _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Maximec 10 mg/ml solution for injection for pigs [IE]
Renomec 10 mg/ml solution for injection for pigs [ES]
Cevamec 10 mg/ml solution for injection for pigs [FR]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains
ACTIVE SUBSTANCE:
Ivermectin
10 mg
EXCIPIENTS:
QUALITATIVE
COMPOSITION OF EXCIPIENTS AND OTHER
CONSTITUENTS
Glycerol
Glycerol formal
A clear, colourless, slightly viscous, non-aqueous solution
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Pigs.
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
Treatment of the infections by the following parasites:
Gastrointestinal roundworms (adult and fourth-stage larvae):
_Ascaris suum _
_Hyostrongylus rubidus _
_Oesophagostomum_
spp.
_Strongyloides ransomi_
(adult)
Lungworms:
_Metastrongylus_
spp. (adult)
Lice:
_Haematopinus suis _
Mange mites:
_Sarcoptes scabiei _
var.
_ suis _
3.3
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance or to
any of the excipients.
Do not use by intramuscular or intravenous administration.
Do not use in cats or dogs as severe adverse reactions may occur.
3.4
SPECIAL WARNINGS
3
Unnecessary use of antiparasitics or use deviating from the
instructions given in the SPC may increase
the resistance selection pressure and lead to reduced efficacy. The
decision to use the veterinary
medicinal product should be based on confirmation of the parasitic
species and burden, or of the risk
of infestation based on its epidemiological features, for each
individual animal or herd.
Repeated use for an extended period, particularly when using the same
class of substances, increases
the risk of resistance development. Within a herd, maintenance of
susceptible refugia is essential to
reduce that risk. Systematically applied interval-based treatment and
treatment of a whole herd should
be avoided. Instead, if feasible, only selected individual animals or
subgroups should be treated
(targeted selective treatment).
                                
                                Leer el documento completo
                                
                            

Buscar alertas relacionadas con este producto